



UNIVERSITY  
of VIRGINIA

ORTHOPAEDIC SURGERY



# Antioxidative Fullerol for Orthopaedic Diseases

Xinlin Yang, PhD

Assistant Professor of Orthopaedics

May 9, 2015



# Research interests

UNIVERSITY  
OF VIRGINIA

- **Fullerene C<sub>60</sub> and orthopaedic diseases**
- **Fullerene C<sub>60</sub> and cell differentiation/function**

**Yang X, Li CJ, Wan Y, Smith P, Shang G, Cui Q.**

Antioxidative fullerol promotes osteogenesis of human adipose-derived stem cells. Int J Nanomedicine. 2014 Aug 20;9:4023-31.

**Yang X, Jin L, Yao L, Shen FH, Shimer AL, Li X.**

Antioxidative nanofullerol prevents intervertebral disk degeneration. Int J Nanomedicine. 2014 May 15;9:2419-30.

**Yang X, Ebrahimi A, Li J, Cui Q.**

Fullerene-biomolecule conjugates and their biomedicinal applications. Int J Nanomedicine. 2014;9:77-92. Review.

**Liu H, Yang X, Zhang Y, Dighe A, Li X, Cui Q.**

Fullerol antagonizes dexamethasone-induced oxidative stress and adipogenesis while enhancing osteogenesis in a cloned bone marrow mesenchymal stem cell. J Orthop Res. 2012 Jul;30(7):1051-7.

**Yang X, Wan Y, Qiao X, Arlet V, Li X**

University of Virginia



Orthopaedic Surgery




# Fullerene C<sub>60</sub>

UNIVERSITY  
OF VIRGINIA


- Drs. Smalley, Curl and Kroto, 1985/1996

## Molecular model of Fullerene C<sub>60</sub>



- Its antioxidative capacity hundreds times higher than...

## Fullerene-ROS interactions (Satoh and Takayanagi, 2006)




NOS: nitric oxide synthase


- 1 NOS inhibition;
- 2 NO scavenging
- 3 Superoxide dismutase mimic




## ➤ Multifactorial diseases



## ➤ Oxidative stress (OS)



(Hendrickx et al., 2015)




- **Oxidative stress** ↑  
**Adipogenesis** ↑
- **Oxidative stress** ↑  
**Osteogenesis** ↓




# OS/OC/inflammation/pathways

UNIVERSITY  
OF VIRGINIA



➤ Oxidative stress ↑  
Osteoclastogenesis ↑



➤ Oxidative stress ↑  
Inflammation ↑







# Biodistribution/Blood clearance

UNIVERSITY  
OF VIRGINIA

## A: Experimental protocol




## B: SPECT imaging



1.5 h post injection

## C: Imaging quantification




## D: Organ distribution

	Time after injection	
	1.5h	48h
Liver	0.262 ± 0.020	0.309 ± 0.048
Kidney	0.097 ± 0.014	0.083 ± 0.011
Spleen	0.735 ± 0.061	0.910 ± 0.097
Cortical bone	0.013 ± 0.002	0.004 ± 0.002*
Femoral bone marrow	0.767 ± 0.107	0.472 ± 0.145
Belly fat	0.003 ± 0.000	0.001 ± 0.000*
Articular cartilage	0.042 ± 0.019	0.018 ± 0.009


\*p<0.05 vs. 1.5h

Data are expressed as a percent of injected dose per gram of tissue (%ID/g.)

- ❖ rabbit
- ❖ TC99m-Fullerol
- ❖ SPECT/
- ❖ γ counter



## E: Blood clearance




- Retained in bone marrow for up to 48 h
- Half time of 1.9 h in blood




# Osteonecrosis

UNIVERSITY  
OF VIRGINIA


A: ARS/mouse D1




B: Gene expression/mouse D1




C: PPAR $\gamma$ /hBMSCs



D: aP2/hBMSCs



F: Oil Red O/hBMSCs



G: Rabbit ONFH model (data is pending)

Group	P	F	S	S+F
MPSL	NO	NO	YES	YES
Nano-Fullerene	NO	Fullerol	NO	Fullerol
Animal number	9	9	11	11

- ❖ D1 & hBMSC
- ❖ Fullerol
- ❖ ARS staining
- ❖ ORO staning
- ❖ qRT-PCR
- ❖ Rabbit
- ❖ MPSL
- ❖ H & E staining






➤ Pending  
histological  
data of FH






# Osteoporosis

UNIVERSITY  
OF VIRGINIA



a, P<0.05 vs group A; b, P<0.05 vs group C




- ❖ RAW264.7
- ❖ RANKL
- ❖ Fullerol
- ❖ Trap staining
- ❖ qRT-PCR
- ❖ Rabbit
- ❖ MPSL
- ❖ Micro-CT

➤ OC ↓  
➤ VB Bone loss ↓



# Disc degeneration

UNIVERSITY  
of VIRGINIA



- ❖ RAW264.7
- ❖ LPS
- ❖ Fullerol
- ❖ qRT-PCR
- ❖ ELISA
- ❖ Rabbit
- ❖ MPSL
- ❖ Micro-CT

➤ Inflammation

➤ IVDD





# Summary

UNIVERSITY  
OF VIRGINIA

- **Fullerol is enriched in the femoral bone marrow.**
- **Fullerol regulates differentiation of bone marrow stem cells and monocytic progenitors.**
- **Fullerene as a powerful antioxidant could potentially be used for treatment of osteonecrosis, osteoporosis and intervertebral disc degeneration.**





# Future Plans

UNIVERSITY  
of VIRGINIA

A.




More  
orthopaedic  
diseases

B.



C.



Novel antioxidative biomaterials

➤ Our R21 on the topic of fullerene-PLGA for bone repair was scored 22. Release profile is being prepared.





# Funding Sources

UNIVERSITY  
OF VIRGINIA

- Orthopaedic Research and Education Foundation/  
Zachary B. Friedenberg Clinician Scientist  
Award (Dr. Cui)
- NIH/NIAMS R21 AR062732 (Dr. Cui)

